title: Novel targeted bladder drug-delivery systems: a review.
abstract: The objective of pharmaceutics is the development of drugs with increased efficacy and reduced side effects. Prolonged exposure of the diseased tissue to the drug is of crucial importance. Drug-delivery systems (DDSs) have been introduced to control rate, time, and place of release. Drugs can easily reach the bladder through a catheter, while systemically administered agents may undergo extensive metabolism. Continuous urine filling and subsequent washout hinder intravesical drug delivery (IDD). Moreover, the low permeability of the urothelium, also described as the bladder permeability barrier, poses a major challenge in the development of the IDD. DDSs increase bioavailability of drugs, therefore improving therapeutic effect and patient compliance. This review focuses on novel DDSs to treat bladder conditions such as overactive bladder, interstitial cystitis, bladder cancer, and recurrent urinary tract infections. The rationale and strategies for both systemic and local delivery methods are discussed, with emphasis on new formulations of well-known drugs (oxybutynin), nanocarriers, polymeric hydrogels, intravesical devices, encapsulated DDSs, and gene therapy. We give an overview of current and future prospects of DDSs for bladder disorders, including nanotechnology and gene therapy.
authors.affiliation: Department of Urogynaecology, King's College Hospital, London, UK.
authors.forename: Martino Maria
authors.initials: MM
authors.lastname: Zacchè
authors.affiliation: Department of Urogynaecology, King's College Hospital, London, UK.
authors.forename: Sushma
authors.initials: S
authors.lastname: Srikrishna
authors.affiliation: Department of Urogynaecology, King's College Hospital, London, UK.
authors.forename: Linda
authors.initials: L
authors.lastname: Cardozo
keywords: bladder disorders; drug targeting; drug-delivery system